PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-10.20%
Negative revenue growth while AVGO stands at 28.68%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-13.82%
Negative gross profit growth while AVGO is at 4.18%. Joel Greenblatt would examine cost competitiveness or demand decline.
-14.40%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-16.11%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-19.40%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-19.33%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-19.46%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.22%
Share reduction more than 1.5x AVGO's 9.44%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.22%
Diluted share reduction more than 1.5x AVGO's 9.37%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
-0.05%
Dividend reduction while AVGO stands at 16.85%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-47.14%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-129.77%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
45.79%
10Y revenue/share CAGR under 50% of AVGO's 829.36%. Michael Burry would suspect a lasting competitive disadvantage.
5.11%
5Y revenue/share CAGR under 50% of AVGO's 83.30%. Michael Burry would suspect a significant competitive gap or product weakness.
-13.52%
Negative 3Y CAGR while AVGO stands at 62.24%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
161.49%
10Y OCF/share CAGR under 50% of AVGO's 1058.30%. Michael Burry would worry about a persistent underperformance in cash creation.
-5.20%
Negative 5Y OCF/share CAGR while AVGO is at 100.36%. Joel Greenblatt would question the firm’s operational model or cost structure.
-44.30%
Negative 3Y OCF/share CAGR while AVGO stands at 39.62%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
169.54%
Below 50% of AVGO's 444.72%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
-6.31%
Negative 5Y net income/share CAGR while AVGO is 149.57%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-36.13%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
89.97%
Below 50% of AVGO's 1194.06%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
105.71%
5Y equity/share CAGR at 50-75% of AVGO's 168.49%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
69.26%
Below 50% of AVGO's 164.37%. Michael Burry suspects a serious short-term disadvantage in building book value.
332.40%
Below 50% of AVGO's 2063.56%. Michael Burry might see weaker long-term distribution growth, raising questions about the firm's capital allocation.
68.60%
5Y dividend/share CAGR at 50-75% of AVGO's 102.46%. Martin Whitman might see a lagging policy in mid-term shareholder returns.
27.51%
3Y dividend/share CAGR at 50-75% of AVGO's 42.45%. Martin Whitman might see a weaker short-term approach to distributing cash.
-6.49%
Firm’s AR is declining while AVGO shows 57.55%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
2.10%
Inventory growth well above AVGO's 1.16%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
7.84%
Asset growth well under 50% of AVGO's 144.12%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
0.29%
Under 50% of AVGO's 167.72%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
20.36%
Debt shrinking faster vs. AVGO's 93.48%. David Dodd sees a safer balance sheet if it doesn't impair future growth.
3.91%
R&D dropping or stable vs. AVGO's 66.28%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
3.88%
SG&A declining or stable vs. AVGO's 276.08%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.